DDInter202 DDInter1658
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Bexarotene {u} (Compound) resembles {v} (Compound) Tamibarotene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
Bexarotene {u} (Compound) binds {v} (Gene) RXRG
Bexarotene {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Bexarotene {u} (Compound) causes {v} (Side Effect) Hypocholesterolaemia
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amlodipine
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Bexarotene (Compound) resembles Tamibarotene (Compound)
Bexarotene (Compound) treats hematologic cancer (Disease)
Bexarotene (Compound) binds RXRG (Gene)
Bexarotene (Compound) is included by Retinoids (Pharmacologic Class)
Bexarotene (Compound) causes Hypocholesterolaemia (Side Effect)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine
Bexarotene may lead to a major life threatening interaction when taken with Cytarabine